181 related articles for article (PubMed ID: 20971741)
1. Combination therapy with epigallocatechin-3-gallate and doxorubicin in human prostate tumor modeling studies: inhibition of metastatic tumor growth in severe combined immunodeficiency mice.
Stearns ME; Amatangelo MD; Varma D; Sell C; Goodyear SM
Am J Pathol; 2010 Dec; 177(6):3169-79. PubMed ID: 20971741
[TBL] [Abstract][Full Text] [Related]
2. Autophagy inhibition contributes to the synergistic interaction between EGCG and doxorubicin to kill the hepatoma Hep3B cells.
Chen L; Ye HL; Zhang G; Yao WM; Chen XZ; Zhang FC; Liang G
PLoS One; 2014; 9(1):e85771. PubMed ID: 24465696
[TBL] [Abstract][Full Text] [Related]
3. Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer.
Liang G; Tang A; Lin X; Li L; Zhang S; Huang Z; Tang H; Li QQ
Int J Oncol; 2010 Jul; 37(1):111-23. PubMed ID: 20514403
[TBL] [Abstract][Full Text] [Related]
4. The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression.
Zhou H; Fu LX; Li L; Chen YY; Zhu HQ; Zhou JL; Lv MX; Gan RZ; Zhang XX; Liang G
J Ethnopharmacol; 2020 Oct; 261():113118. PubMed ID: 32621953
[TBL] [Abstract][Full Text] [Related]
5. In vivo reversal of doxorubicin resistance by (-)-epigallocatechin gallate in a solid human carcinoma xenograft.
Zhang Q; Wei D; Liu J
Cancer Lett; 2004 May; 208(2):179-86. PubMed ID: 15142676
[TBL] [Abstract][Full Text] [Related]
6. (-)-Epigallocatechin-3-gallate alleviates doxorubicin-induced cardiotoxicity in sarcoma 180 tumor-bearing mice.
Yao YF; Liu X; Li WJ; Shi ZW; Yan YX; Wang LF; Chen M; Xie MY
Life Sci; 2017 Jul; 180():151-159. PubMed ID: 27956351
[TBL] [Abstract][Full Text] [Related]
7. Epigallocatechin gallate (EGCG) suppresses growth and tumorigenicity in breast cancer cells by downregulation of miR-25.
Zan L; Chen Q; Zhang L; Li X
Bioengineered; 2019 Dec; 10(1):374-382. PubMed ID: 31431131
[TBL] [Abstract][Full Text] [Related]
8. Epigallocatechin gallate with photodynamic therapy enhances anti-tumor effects in vivo and in vitro.
Mun ST; Bae DH; Ahn WS
Photodiagnosis Photodyn Ther; 2014 Jun; 11(2):141-7. PubMed ID: 24632332
[TBL] [Abstract][Full Text] [Related]
9. EGCG/gelatin-doxorubicin gold nanoparticles enhance therapeutic efficacy of doxorubicin for prostate cancer treatment.
Tsai LC; Hsieh HY; Lu KY; Wang SY; Mi FL
Nanomedicine (Lond); 2016 Jan; 11(1):9-30. PubMed ID: 26654241
[TBL] [Abstract][Full Text] [Related]
10. The activity against Ehrlich's ascites tumors of doxorubicin contained in self assembled, cell receptor targeted nanoparticle with simultaneous oral delivery of the green tea polyphenol epigallocatechin-3-gallate.
Ray L; Kumar P; Gupta KC
Biomaterials; 2013 Apr; 34(12):3064-76. PubMed ID: 23357370
[TBL] [Abstract][Full Text] [Related]
11. The heat shock protein 90 inhibitor, (-)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer progression model.
Moses MA; Henry EC; Ricke WA; Gasiewicz TA
Cancer Prev Res (Phila); 2015 Mar; 8(3):249-57. PubMed ID: 25604133
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanism of epigallocatechin-3-gallate in human esophageal squamous cell carcinoma in vitro and in vivo.
Liu L; Hou L; Gu S; Zuo X; Meng D; Luo M; Zhang X; Huang S; Zhao X
Oncol Rep; 2015 Jan; 33(1):297-303. PubMed ID: 25333353
[TBL] [Abstract][Full Text] [Related]
13. Co-Delivery of Natural Compounds with a Dual-Targeted Nanoparticle Delivery System for Improving Synergistic Therapy in an Orthotopic Tumor Model.
Chu PY; Tsai SC; Ko HY; Wu CC; Lin YH
ACS Appl Mater Interfaces; 2019 Jul; 11(27):23880-23892. PubMed ID: 31192580
[TBL] [Abstract][Full Text] [Related]
14. Dual-effect liposomes with increased antitumor effects against 67-kDa laminin receptor-overexpressing tumor cells.
Sugiyama I; Kaihatsu K; Soma Y; Kato N; Sadzuka Y
Int J Pharm; 2018 Apr; 541(1-2):206-213. PubMed ID: 29486285
[TBL] [Abstract][Full Text] [Related]
15. (-)-Epigallocatechin-3-gallate (EGCG) sensitizes melanoma cells to interferon induced growth inhibition in a mouse model of human melanoma.
Nihal M; Ahsan H; Siddiqui IA; Mukhtar H; Ahmad N; Wood GS
Cell Cycle; 2009 Jul; 8(13):2057-63. PubMed ID: 19502799
[TBL] [Abstract][Full Text] [Related]
16. Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor.
Zhang X; Zhang H; Tighiouart M; Lee JE; Shin HJ; Khuri FR; Yang CS; Chen Z'; Shin DM
Int J Cancer; 2008 Sep; 123(5):1005-14. PubMed ID: 18546267
[TBL] [Abstract][Full Text] [Related]
17. Oral administration of naturally occurring chitosan-based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model.
Khan N; Bharali DJ; Adhami VM; Siddiqui IA; Cui H; Shabana SM; Mousa SA; Mukhtar H
Carcinogenesis; 2014 Feb; 35(2):415-23. PubMed ID: 24072771
[TBL] [Abstract][Full Text] [Related]
18. Green Tea Catechin-Based Complex Micelles Combined with Doxorubicin to Overcome Cardiotoxicity and Multidrug Resistance.
Cheng T; Liu J; Ren J; Huang F; Ou H; Ding Y; Zhang Y; Ma R; An Y; Liu J; Shi L
Theranostics; 2016; 6(9):1277-92. PubMed ID: 27375779
[TBL] [Abstract][Full Text] [Related]
19. SOX2OT variant 7 contributes to the synergistic interaction between EGCG and Doxorubicin to kill osteosarcoma via autophagy and stemness inhibition.
Wang W; Chen D; Zhu K
J Exp Clin Cancer Res; 2018 Feb; 37(1):37. PubMed ID: 29475441
[TBL] [Abstract][Full Text] [Related]
20. Effect of selected catechins on doxorubicin antiproliferative efficacy and hepatotoxicity in vitro.
Rudolfová P; Hanušová V; Skálová L; Bártíková H; Matoušková P; Boušová I
Acta Pharm; 2014 Jun; 64(2):199-209. PubMed ID: 24914720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
